Deficiency in sPLA(2) does not affect HDL levels or atherosclerosis in mice

Area of Science:

• Cardiovascular Biology
• Inflammation Research
• Lipid Metabolism

Background:

• Secretory non-pancreatic phospholipase A(2) (sPLA(2)) is linked to inflammation and present in human atherosclerotic lesions.
• Investigating the role of sPLA(2) in atherosclerosis is crucial for understanding cardiovascular disease.
• Genetic deficiency of sPLA(2) provides a model to study its specific contribution.

Purpose of the Study:

• To determine the effect of secretory non-pancreatic phospholipase A(2) (sPLA(2)) deficiency on the development of atherosclerosis.
• To assess the impact of sPLA(2) genotype on lipid profiles and cholesterol levels.
• To evaluate the role of endogenous sPLA(2) in a mouse model of atherosclerosis.

Main Methods:

• Cross-breeding of C57BL/Ks mice (apoE(+/+) and PLA(2)(++)) with C57BL/6 apoE knockout mice to generate sPLA(2)(-/-) and sPLA(2)(+/+) littermates.
• Feeding mice a high-fat Western diet for 22 weeks.
• In vitro enzyme assays, FPLC analysis of lipoprotein profiles, and quantification of aortic cholesterol content.

Main Results:

• Serum sPLA(2) activity was higher in sPLA(2)(++) mice compared to sPLA(2)(-/-) mice.
• sPLA(2)(-/-) males exhibited slightly elevated serum cholesterol and phospholipids, but FPLC showed no genotype effect on lipoprotein profiles.
• No statistically significant differences in aortic cholesterol content (atherosclerosis) were observed between sPLA(2) genotypes in either sex.

Conclusions:

• Endogenous secretory non-pancreatic phospholipase A(2) (sPLA(2)) does not significantly influence high-density lipoprotein (HDL) levels or atherosclerosis development in this mouse model.
• The study suggests a limited role for the endogenous mouse sPLA(2) gene in the pathogenesis of atherosclerosis.
• Further research may be needed to explore other sPLA(2) isoforms or different experimental conditions.